New Topics in Vasopressin Receptors and Approach to Novel Drugs: Vasopressin and Pain Perception

Journal of Pharmacological Sciences

Gozoh Tsujimoto²  Taka-aki Koshimizu¹ 

[1] Division of Molecular Pharmacology, Department of Pharmacology, Jichi Medical University, Japan;Department of Genomic Drug Discovery Science, Kyoto University Graduate School of Pharmaceutical Sciences, Japan

关键词: arginine vasopressin;    oxytocin;    pain;    nociception;    V1a receptor;    V1b receptor;   

DOI  :  10.1254/jphs.08R18FM

学科分类：药学

来源: Nihon Yakuri Gakkai Henshuubu / Japanese Pharmacological Society

【 摘 要 】

References(59)Cited-By(6)Arginine vasopressin (AVP) activates three vasopressin receptors and it also has an agonistic activity on the oxytocin receptor. For an accurate description of the target receptor subtype(s) responsible for complex AVP and oxytocin actions, a careful evaluation of ligand specificity and receptor activities are required, particularly when these receptors are co-expressed in the central nervous system. Previous studies suggest that AVP plays a regulatory role in nociception through the direct activation of central vasopressin receptors and also through the receptors that reside in the peripheral tissues. Genetically altered rodent models, including the AVP-deficient mutant Brattleboro rat and gene knockout mice lacking an endogenous opioid peptide, advanced the understanding of the interactions between the pain perception process and AVP system. This report reviews previous findings in this important field and reconciles them with the findings of recent gene knockout/knockdown studies.

【 授权许可】

Unknown